The human gastrointestinal tract is a complex ecosystem, and Bifidobacterium species are among its most vital residents. As a leading Contract Research Organization (CRO), Creative Biolabs is at the forefront of transforming these beneficial bacteria from simple dietary supplements into sophisticated bio-therapeutic delivery vehicles. By integrating RNA interference (RNAi) technology with the natural colonization capabilities of Bifidobacterium, we offer a groundbreaking platform for targeted gene silencing within the gut. This synergy allows for the localized treatment of gastrointestinal diseases, metabolic disorders, and systemic conditions with unprecedented precision. This technology leverages the natural symbiotic relationship between Bifidobacterium and the human host to deliver gene-silencing molecules directly to the intestinal mucosa. By engineering these "next-generation probiotics," we provide a solution to the long-standing challenge of oral RNAi delivery: surviving the gastrointestinal transit to achieve localized, potent, and safe gene knockdown.
Overview: The Mechanism of Action
RNA interference is a highly specific biological process where double-stranded RNA (dsRNA) molecules induce the degradation of complementary messenger RNA (mRNA). This effectively "silences" the gene, preventing the production of disease-associated proteins. While the therapeutic potential of RNAi is vast, systemic delivery via lipid nanoparticles (LNPs) often fails to reach the gut in sufficient concentrations or leads to off-target effects in the liver.
Why Bifidobacterium?
Bifidobacterium spp. serve as the perfect "Trojan Horse" for RNAi delivery:
-
Anaerobic Niche: They thrive in the low-oxygen environment of the colon.
-
Safety Profile: As GRAS (Generally Recognized as Safe) organisms, they have a long history of human consumption.
-
Natural Adhesion: They possess specialized surface proteins (pili and adhesins) that allow them to persist in the intestinal mucosa, right where the therapeutic action is needed.
The Engineering Process
We engineer Bifidobacterium strains to carry a specialized plasmid vector. Once these bacteria colonize the intestinal tract, they transcribe short hairpin RNA (shRNA). These molecules are then released into the host environment, either through secretion systems or controlled bacterial lysis, where they enter host epithelial or immune cells to silence specific disease-driving genes.
Our Services
We provide an end-to-end pipeline for customers looking to develop next-generation probiotics or live biotherapeutic products (LBPs).
Custom Strain Engineering
-
Strain Selection: Choose from our proprietary library of B. longum, B. breve, and B. infantis, or provide your own isolate.
-
Plasmid Design: Optimization of promoters (constitutive or inducible) to ensure high-level expression of shRNA.
-
Gene Editing Integration: For stable, markerless integration of RNAi cassettes into the bacterial chromosome.
Target Validation & Screening
-
Bioinformatics Pipeline: Identification of optimal mRNA target sequences to ensure high silencing efficiency and minimal off-target effects.
-
In Vitro Testing: Validation of gene knockdown in intestinal cell lines (e.g., Caco-2, HT-29) using qPCR and Western Blotting.
In Vivo Efficacy Studies
-
Pharmacokinetics: Tracking bacterial colonization persistence and RNAi expression levels in the gut.
-
Disease Models: Testing in specialized animal models, including DSS-induced colitis, high-fat diet obesity models, and colorectal cancer xenografts.
Related Products
To support your internal R&D, we offer a suite of specialized products:
-
RNAi Expression Vectors: Modular plasmids with various selection markers (e.g., Erythromycin, Spectinomycin) and gut-active promoters.
Broad Application Fields
The versatility of the Bifidobacterium-RNAi platform allows it to span multiple therapeutic areas:
-
Inflammatory Bowel Disease (IBD): Silencing pro-inflammatory cytokines such as TNF-α or IL-1β directly at the site of inflammation.
-
Metabolic Disorders: By targeting genes like SREBP-1c (involved in lipid synthesis) or FASN (fatty acid synthase) in the intestinal epithelium, our engineered bacteria can modulate host metabolism to combat obesity and non-alcoholic fatty liver disease (NAFLD).
-
Colorectal Cancer (CRC): Recent studies show that certain Bifidobacterium strains naturally accumulate in the hypoxic centers of solid tumors. We are developing strains that deliver RNAi targeting PD-L1 or other immune checkpoints, turning the cold tumor microenvironment "hot" and enhancing the efficacy of traditional immunotherapies.
-
Intestinal Infections: Silencing virulence factors of enteric pathogens without disrupting the broader microbiome.
Why Partner With Us?
Proprietary Transformation Protocols
Bifidobacterium is notoriously difficult to transform. We have developed proprietary electroporation and conjugation methods that yield significantly higher transformation efficiencies than standard academic protocols.
Strict Quality Control
Every engineered strain undergoes whole-genome sequencing (WGS) to ensure genetic stability and the absence of unintended mutations.
Regulatory Expertise
We assist in navigating the complex regulatory landscape for Genetically Modified Organisms (GMOs) and Live Biotherapeutic Products.
Scalability
From lab-scale fermentation to pilot-scale production, we ensure your technology is ready for clinical translation.
Drive Your Research Forward
The integration of RNAi technology into Bifidobacterium represents a paradigm shift in how we treat chronic disease. No longer are we limited to systemic pills or painful injections; the future of medicine is "living," localized, and incredibly precise. The future of gastroenterology lies in the intersection of microbiology and genetic engineering. By leveraging our Bifidobacterium spp.-mediated RNAi platform, you can bypass the systemic side effects of traditional drugs and deliver therapy exactly where it's needed.
Would you like me to generate a detailed case study document or a formal quote for a pilot strain engineering project?
Frequently Asked Questions (FAQs)
Is the RNAi effect permanent?
No. The silencing effect is transient and depends on the presence of the engineered Bifidobacterium. Once the administration stops, the bacteria are naturally cleared from the system, providing a built-in safety "off-switch."
How do the RNAi molecules enter the host cells?
While research is ongoing, evidence suggests that Bifidobacterium can release RNAi triggers via extracellular vesicles (EVs) or that localized high concentrations allow for uptake through endocytic pathways in the intestinal epithelium.
Can these bacteria transfer their engineered DNA to other gut microbes?
We prioritize safety by using "non-mobilizable" plasmids and chromosomal integration techniques that minimize the risk of horizontal gene transfer (HGT).
